MedPath

DRI HEALTHCARE TRUST

🇨🇦Canada
Ownership
-
Employees
-
Market Cap
$530.9M
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

No trials found

News

DRI Healthcare Trust Acquires Royalty Interest in KalVista's Seb способов лечения Hereditary Angioedema Drug

DRI Healthcare Trust has acquired a royalty interest in sebetralstat, an oral on-demand therapy for hereditary angioedema (HAE), from KalVista Pharmaceuticals.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.